Patents Assigned to FibroGen, Inc.
  • CONNECTIVE TISSUE GROWTH FACTOR ANTIBODIES
    Publication number: 20190023778
    Abstract: The present invention relates to antibodies that bind to CTGF. The antibodies are particularly directed to regions of CTGF involved in biological activities associated with fibrosis. The invention also relates to methods of using the antibodies to treat disorders associated with CTGF including localized and systemic fibrotic disorders including those of the lung, liver, heart, skin, and kidney.
    Type: Application
    Filed: October 10, 2018
    Publication date: January 24, 2019
    Applicant: FibroGen, Inc.
    Inventors: Al Y. LIN, Thomas B. Neff, Noelynn A. Oliver, William R. Usinger, Qingjian Wang, David A. Yeowell
  • METHODS FOR TREATMENT OF MOTOR NEURON DISEASES
    Publication number: 20190002547
    Abstract: The invention relates to methods and agents useful for treating motor neuron diseases (MNDs), in particular, amyotrophic lateral sclerosis (ALS). Methods and agents for treating various physiological and pathological conditions associated with motor neuron diseases are also provided.
    Type: Application
    Filed: December 6, 2016
    Publication date: January 3, 2019
    Applicant: FibroGen, Inc.
    Inventors: Enrique BRANDAN, David GONZALEZ
  • Crystalline forms of a prolyl hydroxylase inhibitor
    Patent number: 10118897
    Abstract: The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: November 6, 2018
    Assignee: FibroGen, Inc.
    Inventors: Claudia Witschi, Jung Min Park, Michael D. Thompson, Michael John Martinelli, David A. Yeowell, Michael P. Arend
  • METHODS FOR TREATING IDIOPATHIC PULMONARY FIBROSIS
    Publication number: 20180310906
    Abstract: The present invention relates to methods and medicaments useful for treating idiopathic pulmonary fibrosis (IPF) by administering anti-CTGF antibodies. Methods for prognosing individuals with IPF are also provided.
    Type: Application
    Filed: July 5, 2018
    Publication date: November 1, 2018
    Applicant: FibroGen, Inc.
    Inventors: Seth Porter, John L. Stauffer
  • Nitrogen-containing heteroaryl compounds and methods of use thereof
    Patent number: 10092558
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: October 9, 2018
    Assignee: FibroGen, Inc.
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric D. Turtle, Xiaohui Du
  • Methods for treating idiopathic pulmonary fibrosis
    Patent number: 10039515
    Abstract: The present invention relates to methods and medicaments useful for treating idiopathic pulmonary fibrosis (IPF) by administering anti-CTGF antibodies. Methods for prognosing individuals with IPF are also provided.
    Type: Grant
    Filed: September 13, 2016
    Date of Patent: August 7, 2018
    Assignee: FIBROGEN, INC.
    Inventors: Seth Porter, John L Stauffer
  • Crystalline forms of a prolyl hydroxylase inhibitor
    Patent number: 9918977
    Abstract: The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: March 20, 2018
    Assignee: FibroGen, Inc.
    Inventors: Claudia Witschi, Jung Min Park, Michael D. Thompson, Michael John Martinelli, David A. Yeowell, Michael P. Arend
  • Enhanced erythropoiesis and iron metabolism
    Patent number: 9920011
    Abstract: The present invention relates to methods and compounds for regulating or enhancing erythropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.
    Type: Grant
    Filed: November 19, 2013
    Date of Patent: March 20, 2018
    Assignee: FibroGen, Inc.
    Inventors: Stephen J. Klaus, Christopher J. Molineaux, Thomas B. Neff, Volkmar Guenzler-Pukall, Robert C. Stephenson, Todd W. Seeley, Ingrid Langsetmo Parobok
  • METHODS FOR TREATING A NEUROLOGICAL DISORDER IN A SUBJECT USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) PROYL HYDROXYLASE
    Publication number: 20170312268
    Abstract: The present invention provides methods for treating anemia in a subject having kidney failure by administering a compound that inhibits hypoxia-inducible factor (HIF) prolyl hydroxylase.
    Type: Application
    Filed: February 3, 2017
    Publication date: November 2, 2017
    Applicant: FibroGen, Inc.
    Inventors: Stephen J. KLAUS, Al Y. Lin, Thamas B. Neff, Qingjian Wang, Volkmar Guenzler-Pukall, Lee A. Flippin, Michael P. Arend, Alex Melekhov
  • Compounds and methods for treatment of stroke
    Patent number: 9775902
    Abstract: The present invention relates to methods and agents useful for the treatment of stroke, including ischemic stroke and hemorrhagic stroke. In particular, methods and agents for treating stroke in a subject are provided, wherein the agent is administered prior to diagnosis of the stroke as an ischemic stroke or a hemorrhagic stroke.
    Type: Grant
    Filed: July 11, 2011
    Date of Patent: October 3, 2017
    Assignee: FIBROGEN, INC
    Inventors: Stephen J. Klaus, Ingrid Langsetmo Parobok, Christopher T. Jacob
  • Process for making isoquinoline compounds
    Patent number: 9708269
    Abstract: The present invention relates to methods for making isoquinoline compounds and the intermediate compounds achieved thereby. Such compounds can be used to prepare compounds and compositions capable of decreasing HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: July 18, 2017
    Assignee: FibroGen, Inc.
    Inventors: Michael D. Thompson, Jung Min Park, Michael P. Arend
  • Naphthyridine derivatives as inhibitors of Hypoxia inducible factor (HIF) hydroxylase
    Patent number: 9695170
    Abstract: The present disclosure relates to novel compounds, methods, and compositions capable of inhibiting HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: July 4, 2017
    Assignee: FibroGen, Inc.
    Inventors: Danny Ng, Michael P. Arend, Lee A. Flippin
  • Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
    Patent number: 9643928
    Abstract: The present disclosure relates to crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid (Compound A), the process of preparing crystalline forms of Compound A, the pharmaceutical compositions containing them, and the methods of use thereof.
    Type: Grant
    Filed: January 23, 2014
    Date of Patent: May 9, 2017
    Assignee: FibroGen, Inc.
    Inventors: Claudia Witschi, Michael D. Thompson, Jung Min Park, Michael P. Arend
  • Therapeutic method for pancreatic cancer
    Patent number: 9631013
    Abstract: The present invention relates to methods and medicarnents useful for treating locally advanced pancreatic cancer (LAPC). Improved therapeutic methods and regimens comprising anti-connective tissue growth factor (CTGF) agents, including anti-CTGF antibodies, are provided. Included are induction therapies for converting unreseetable LAPC into borderline or resectable status.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: April 25, 2017
    Assignee: FIBROGEN, INC.
    Inventors: Katharina Modelska, Frank Valone, Vincent Picozzi, Wen Shi
  • Crystalline forms of a prolyl hydroxylase inhibitor
    Patent number: 9617218
    Abstract: The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: April 11, 2017
    Assignee: FibroGen, Inc.
    Inventors: Claudia Witschi, Jung Min Park, Michael D. Thompson, Michael John Martinelli, David A. Yeowell, Michael P. Arend
  • Treatment method for lung remodeling diseases
    Patent number: 9587016
    Abstract: The present invention relates to methods and medicaments useful for pre-treatment, treatment, or amelioration of lung remodeling disease. Methods and medicaments for reducing, preventing, or reversing increased lung density, improving lung function, and increasing survivability in subjects having lung remodeling disease are also provided.
    Type: Grant
    Filed: June 17, 2015
    Date of Patent: March 7, 2017
    Assignee: FIBROGEN, INC.
    Inventor: Kenneth E. Lipson
  • METHODS FOR TREATING IDIOPATHIC PULMONARY FIBROSIS
    Publication number: 20170027535
    Abstract: The present invention relates to methods and medicaments useful for treating idiopathic pulmonary fibrosis (IPF) by administering anti-CTGF antibodies. Methods for prognosing individuals with IPF are also provided.
    Type: Application
    Filed: September 13, 2016
    Publication date: February 2, 2017
    Applicant: FibroGen, Inc.
    Inventors: SETH PORTER, John L. Stauffer
  • Methods for treating idiopathic pulmonary fibrosis
    Patent number: 9480449
    Abstract: The present invention relates to methods and medicaments useful for treating idiopathic pulmonary fibrosis (IFF) by administering anti-CTGF antibodies. Methods for prognosing individuals with IPF are also provided.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: November 1, 2016
    Assignee: FIBROGEN, INC.
    Inventors: Seth Porter, John L Stauffer
  • Connective Tissue Growth Factor Antibodies
    Publication number: 20160257740
    Abstract: The present invention relates to antibodies that bind to CTGF. The antibodies are particularly directed to regions of CTGF involved in biological activities associated with fibrosis. The invention also relates to methods of using the antibodies to treat disorders associated with CTGF including localized and systemic fibrotic disorders including those of the lung, liver, heart, skin, and kidney.
    Type: Application
    Filed: May 25, 2016
    Publication date: September 8, 2016
    Applicant: FibroGen, Inc.
    Inventors: Al Y. Lin, Thomas B. Neff, Noelynn A. Oliver, William R. Usinger, Qingjian Wang, David A. Yeowell
  • 4-hydroxy-isoquinoline compounds as HIF hydroxylase inhibitors
    Patent number: 9409892
    Abstract: The present invention relates to novel compounds of formula (I), and compositions capable of inhibiting PHD1 enzyme activity selectively over other isoforms, for example, PHD2 and/or PHD3 enzymes. The invention also relates to compounds of formula (I) for use in disorders such as muscle degeneration, colitis, IBD, and certain ischemias.
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: August 9, 2016
    Assignee: FibroGen, Inc.
    Inventors: Wen-Bin Ho, Hongda Zhao, Shaojiang Deng, Danny Ng, Lee R. Wright, Min Wu, Xiaoti Zhou, Michael P. Arend, Lee A. Flippin